In this Issue
- Reflecting on UW Madison’s Fourth Annual Psychedelic Symposium
- MindMed Doses First Patient in Phase 3 LSD Program
- Beckley Psytech Shares Small Cut of Data from Phase 2a Study of IV Psilocin in MDD
- Trial Suggests Psilocybin Could Help Clinicians With COVID-Related Mental Health Issues
- Naropa Spins Off Psychedelics Centre to Avoid Federal Illegality
- Awakn Life Sciences Set to Be Acquired
- and more…
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue